Lääkealan turvallisuus- ja kehittämiskeskus Fimea - Selaus tekijän mukaan "Huys, I."

Background: Orphan designated medicinal products benefit from regulatory and economic incentives for orphan drug development. Approximately 40% of orphan designations target rare neoplastic disorders, referring to rare ...